ANGO - AngioDynamics shares rise on Q4 topline beat FY forecast

AngioDynamics shares rise ([[ANGO]] +2.1%) after the company posted fourth-quarter revenue that beat Wall Street estimates, helped by the strength in its endovascular therapies business, and provided a financial forecast for the year.Net sales during the quarter rose 32% to $76.84M, beating analysts' average estimate by $4.17M.Endovascular therapies net sales were $38.1M, an increase of 72.3% YOY, driven by sales of the company's Auryon and AngioVac platforms.Oncology net sales were $14.3M, an increase of 14.2%, compared to $12.5M in the prior-year period.The company expects its fiscal year 2022 net sales to be in the range of $305M to $310M, gross margin to be about 55.0% and adjusted earnings per share in the range of $0.00 to $0.05.The company recorded a net loss of $19.5M, or $0.51 per share, in the fourth quarter of fiscal 2021 compared to a net loss of $157M, or $4.13 per share, a year ago.The current-year net

For further details see:

AngioDynamics shares rise on Q4 topline beat, FY forecast